3 hours ago
1
Justin Sullivan/Getty Images News
Gilead Sciences (NASDAQ:GILD) on Wednesday announced a collaboration with the Swiss non-profit The Global Fund to accelerate access to lenacapavir, its newly approved HIV PrEP therapy, for people living mainly in low- and lower-middle-income countries.
Under the partnership, Gilead (
English (US) ·